Presented by expert speakers from leading pharmaceutical companies, these workshops will give you advanced insights into topic areas that the event will address
Can’t make the date? Still register to receive the recording afterwards.
Targeted, Controlled and Responsive Therapeutic Delivery through the Design of Self-Assembling Peptide Hydrogels
Tuesday 14th January 2020 | 2PM GMT
Presented by Aline Miller, Professor, University of Manchester
- Design rules for engineering responsive peptide hydrogels
- Targeting endometriosis with sprayable peptide hydrogels
- Delivery of therapeutics to solid tumours
- Mucoadhesive hydrogels to prolong therapeutic efficacy
Aline Miller, PhD, is a Professor of Biomolecular Engineering in the School of Chemical Engineering at the University of Manchester where she has won several awards, including The Royal Society of Chemistry MacroGroup UK Young Researchers Medal, The Institute of Physics, Polymer Physics Group Young Researchers Lecture Award and the Philip Leverhulme Prize for Engineering for her work on self-assembling peptide materials. In this area she has published over 100 refereed papers, authored 5 patents and has won > £8M from research councils, EU, charities and industry to support her research group. Aline is also Chief Executive Officer and Co-Founder of Manchester BIOGEL, a company specialising in providing engineered, self-assembling peptide hydrogels for 3D cell culture, 3D bioprinting and incorporation within medical devices. She currently oversees all aspects of the business from product production and development, to marketing and sales, to ensure our customers receive the very best product and service.
Our free webinar is for peptide professionals based in the UK, EU and US interested in learning more about the opportunities and challenges that exist within peptide targeted therapeutic delivery. This is a free event open to all, so why not register and benefit from the expertise of our speakers.
Bispecifics Digital Workshops
BISPECIFICS: DISCOVERY & PLATFORM DEVELOPMENT | 2nd July
Using CrossMab Technology For Development Of Bispecific Antibodies
Thursday 2nd July 2020 | 14:00 - 14:25 BST
CHRISTIAN KLEIN, Department Head Cancer Immunotherapy Discovery 3, Roche Innovation Center Zurich
- Basis of CrossMab technology
- Engineering features of CrossMabs and application of CrossMab technology for generation of diverse set of bispecific antibody formats
- CrossMabs in development incuding antiangiogenesis, checkpoint inhibition, T cell bispecific antibodies and antibody fusion proteins
- Examples of CrossMabs in academic research
Bispecific ADCs Targeting HER2: Intracellular Trafficking Of The Antibody Dictates The Choice Of Linker-Payload
Thursday 2nd July 2020 | 14:25 - 14:50 BST
JULIAN ANDREEV, Research Fellow, Regeneron
Bispecific ADCs bridging HER2 and high turnover proteins travel to lysosomes and improve efficacy of HER2 ADCs with non-cleavable linker-DM1. Biparatopic HER2 ADCs induce target internalization and require cleavable linker for greater efficacy. Combining various bispecific antibody approaches with correct linker-payload technology may allow to generate ADCs with better efficacy and safety profiles.
Fusions And DutaFabs: An Update On Roche’s Bispecific Platforms
Thursday 2nd July 2020 | 14:50 - 15:15 BST
MARLON HINNER, Principal Scientist & Group Leader, Roche Innovation Centre Munich
Bi- and multispecific antibodies facilitate novel modes of action for the treatment of diseases including but not limited to immuno-oncology and autoimmunity. With multiple bispecifics programs in pre-clinical and clinical development, Roche is constantly increasing its experience and expertise in this area. In this presentation an update on new and existing bispecific antibody formats and their applications will be provided.
Targeting Solid Tumors With Bispecifics
Thursday 2nd July 2020 | 15:15 - 15:40 BST
DANIELLE MANDIKIAN, Scientist, Genentech
Danielle Mandikian’s talk will cover her cover-featured manuscript published in MCT in 2018, which won ‘Most Cited Article’. The focus of this work was on the design of T Cell Dependent Bispecific Antibodies for solid tumor targeting. This research highlighted the impact of CD3 targeting affinity and relative HER2/CD3 affinity as critical drivers for TDB distribution in vivo.